< 回列表
吳尚俊 Shang-Gin Wu
- 臺大癌醫中心分院綜合內科部 副主任
Recent Advances in Treatment for Small Cell Lung Cancer
| 角色 | 講師 |
| 日期時間 | 05/02 15:50 - 16:30 |
| 地點 | 701B |
學歷 / 訓練
2003, M.D., 台北醫學大學
2016, PhD., 台灣大學
專業與研究經歷
2021 - 2023, 台灣胸腔暨重症加護醫學會 副秘書長
2021 - 2023, 台灣胸腔暨重症加護醫學會肺腫瘤委員會 執行秘書
2021 - 2025, 教育部 部定副教授
2022 - Present, 臺大癌醫中心分院綜合內科部 副主任
2025 - Present, 教育部 部定教授
獲獎與榮譽
2020
Oral Presentation (Best Study)：MiR-204 reverses osimertinib resistance through targeting CD44 and decreasing EMT and stemness
2021
Oral Presentation (Best Research)：The Impact of Concomitant EGFR Mutations on the Treatment Effectiveness of EGFR TKIs for NSCLC patients with L858R
2022
Oral Presentation (第一名)：Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR
2023
Poster Presentation (臨床組優秀論文獎)：The Molecular and Immunological Alterations in Blood during EGFR-TKI Treatment in patient with EGFRL858R Mutant NSCLC.
2024
Poster presentation (優秀海報)：Real-World Treatment Patterns and Outcomes of Post-Osimertinib Therapy in Advanced EGFR-Mutant NSCLC Patients in Taiwan.
重要出版品
- Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR. Int J Cancer. 2023 Jul 15;153(2):352-363. (First author)
- miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44. Mol Ther Nucleic Acids. 2023 Dec 5;35(1):102091. (First author)
- Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Clin Transl Med. 2025 Jan;15(1):e70149. (First author)
- Chen YC, Hsu CL, Wang HM, Wu SG, Chang YL, Chen JS, Wu YC, Lin YT, Yang CY, Lin MW, Lee JM, Kuo SW, Chen KC, Hsu HH, Huang PM, Huang YL, Yu CJ, Pirooznia M, Huang BE, Yang R, Shih JY, Yang PC. Multi-omics Analysis Reveals Molecular Changes During Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-Smokers. Cancer Res. 2025 Feb 1;85(3):602-617. (Co-First author)
- Recommendations on the management of kinase inhibitor-associated hyperlipidemia in patients with lung cancer. Cancer Treat Rev. 2025 Dec 8:143:103065. (Co-First author)